Migraine Briefs

Key clinical point: Survey findings from a real-world tertiary headache clinic support the efficacy and safety of ubrogepant for acute treatment of migraine.

Major finding: Complete headache freedom and headache relief at 2 hours after taking ubrogepant for at least 75% of treated attacks were achieved in 19.0% and 47.6% of patients with migraine, respectively. Overall, 31.1% of patients reported being very satisfied with ubrogepant. Rates of adverse events were higher than those observed in clinical trials. However, no severe/serious adverse events were reported.

Study details: The data come from an analysis of questionnaire responses of 106 adult patients with migraine with or without aura treated with ubrogepant at a tertiary headache center.

Disclosures: No source of funding was declared. DW Dodick declared research support/consulting from various sources. AJ Starling declared consulting fees from Alder, Allergan, Amgen, Axsome Therapeutics, and others. Four of the other authors had no disclosures.

Source: Chiang C-C et al. Headache. 2021 Feb 5. doi: 10.1111/head.14062.

Key clinical point: Survey findings from a real-world tertiary headache clinic support the efficacy and safety of ubrogepant for acute treatment of migraine.

Major finding: Complete headache freedom and headache relief at 2 hours after taking ubrogepant for at least 75% of treated attacks were achieved in 19.0% and 47.6% of patients with migraine, respectively. Overall, 31.1% of patients reported being very satisfied with ubrogepant. Rates of adverse events were higher than those observed in clinical trials. However, no severe/serious adverse events were reported.

Study details: The data come from an analysis of questionnaire responses of 106 adult patients with migraine with or without aura treated with ubrogepant at a tertiary headache center.

Disclosures: No source of funding was declared. DW Dodick declared research support/consulting from various sources. AJ Starling declared consulting fees from Alder, Allergan, Amgen, Axsome Therapeutics, and others. Four of the other authors had no disclosures.

Source: Chiang C-C et al. Headache. 2021 Feb 5. doi: 10.1111/head.14062.

Key clinical point: Survey findings from a real-world tertiary headache clinic support the efficacy and safety of ubrogepant for acute treatment of migraine.

Major finding: Complete headache freedom and headache relief at 2 hours after taking ubrogepant for at least 75% of treated attacks were achieved in 19.0% and 47.6% of patients with migraine, respectively. Overall, 31.1% of patients reported being very satisfied with ubrogepant. Rates of adverse events were higher than those observed in clinical trials. However, no severe/serious adverse events were reported.

Study details: The data come from an analysis of questionnaire responses of 106 adult patients with migraine with or without aura treated with ubrogepant at a tertiary headache center.

Disclosures: No source of funding was declared. DW Dodick declared research support/consulting from various sources. AJ Starling declared consulting fees from Alder, Allergan, Amgen, Axsome Therapeutics, and others. Four of the other authors had no disclosures.

Source: Chiang C-C et al. Headache. 2021 Feb 5. doi: 10.1111/head.14062.

Key clinical point: Inadequate magnesium consumption through the diet is associated with migraine in US adults, aged 20-50 years.

Major finding: Only 26.1% of participants with migraine met their recommended dietary allowance (RDA) for magnesium through diet and supplements. Attainment of the RDA for magnesium through diet and supplements was associated with lower odds of migraine (adjusted odds ratio, 0.83; P = .035).

Study details: An analysis of cross-sectional data of 3,626 individuals aged 20-50 years from the National Health and Nutrition Examination Survey (2001-2004) who were categorized into migraine (n=905) and control (n=2,721) groups.

 Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Source: Slavin M et al. Headache. 2021 Jan 27. doi: 10.1111/head.14065.

Key clinical point: Inadequate magnesium consumption through the diet is associated with migraine in US adults, aged 20-50 years.

Major finding: Only 26.1% of participants with migraine met their recommended dietary allowance (RDA) for magnesium through diet and supplements. Attainment of the RDA for magnesium through diet and supplements was associated with lower odds of migraine (adjusted odds ratio, 0.83; P = .035).

Study details: An analysis of cross-sectional data of 3,626 individuals aged 20-50 years from the National Health and Nutrition Examination Survey (2001-2004) who were categorized into migraine (n=905) and control (n=2,721) groups.

 Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Source: Slavin M et al. Headache. 2021 Jan 27. doi: 10.1111/head.14065.

Key clinical point: Inadequate magnesium consumption through the diet is associated with migraine in US adults, aged 20-50 years.

Major finding: Only 26.1% of participants with migraine met their recommended dietary allowance (RDA) for magnesium through diet and supplements. Attainment of the RDA for magnesium through diet and supplements was associated with lower odds of migraine (adjusted odds ratio, 0.83; P = .035).

Study details: An analysis of cross-sectional data of 3,626 individuals aged 20-50 years from the National Health and Nutrition Examination Survey (2001-2004) who were categorized into migraine (n=905) and control (n=2,721) groups.

 Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Source: Slavin M et al. Headache. 2021 Jan 27. doi: 10.1111/head.14065.

Key clinical point: Percutaneous patent foramen ovale (PFO) closure with the Amplatzer PFO Occluder significantly reduced migraine days and attacks in patients with episodic migraine who had PFO and were refractory to preventive medical therapy.

Major finding: At 12 months, PFO closure vs. medical therapy group showed a significantly greater mean reduction in monthly migraine days (−3.1 vs. −1.9 days; P = .02) and the number of monthly migraine attacks (−2.0 vs. −1.4; P = .01). Rate of complete migraine cessation was significantly higher in PFO closure vs. medical therapy (9% vs. 0.7%; P less than .001) group. No clinically relevant adverse events were reported.

Study details: Findings are from individual patient-level data from 2 randomized migraine trials PRIMA and PREMIUM involving 337 patients with episodic migraine and PFO randomly allocated to either PFO closure+medical therapy (n=176) or medical therapy alone (n=161).

Disclosures: The study did not receive any funding. Dr. AC Charles, Dr. S Sorensen, Dr. SD Silberstein and Dr. JM Tobis were on the steering committee for the PREMIUM trial. Dr. HP Mattle and Dr. B Meier were on the steering committee for the PRIMA trial.  Dr. B West, Dr. B Meier and Dr. JM Tobis declared receiving funds, serving as proctor/speaker/consultant for various sources. All other authors declared no conflicts of interest.

Source: Mojadidi MK et al. J Am Coll Cardiol. 2021 Feb 16. doi: 10.1016/j.jacc.2020.11.068.

Key clinical point: Percutaneous patent foramen ovale (PFO) closure with the Amplatzer PFO Occluder significantly reduced migraine days and attacks in patients with episodic migraine who had PFO and were refractory to preventive medical therapy.

Major finding: At 12 months, PFO closure vs. medical therapy group showed a significantly greater mean reduction in monthly migraine days (−3.1 vs. −1.9 days; P = .02) and the number of monthly migraine attacks (−2.0 vs. −1.4; P = .01). Rate of complete migraine cessation was significantly higher in PFO closure vs. medical therapy (9% vs. 0.7%; P less than .001) group. No clinically relevant adverse events were reported.

Study details: Findings are from individual patient-level data from 2 randomized migraine trials PRIMA and PREMIUM involving 337 patients with episodic migraine and PFO randomly allocated to either PFO closure+medical therapy (n=176) or medical therapy alone (n=161).

Disclosures: The study did not receive any funding. Dr. AC Charles, Dr. S Sorensen, Dr. SD Silberstein and Dr. JM Tobis were on the steering committee for the PREMIUM trial. Dr. HP Mattle and Dr. B Meier were on the steering committee for the PRIMA trial.  Dr. B West, Dr. B Meier and Dr. JM Tobis declared receiving funds, serving as proctor/speaker/consultant for various sources. All other authors declared no conflicts of interest.

Source: Mojadidi MK et al. J Am Coll Cardiol. 2021 Feb 16. doi: 10.1016/j.jacc.2020.11.068.

Key clinical point: Percutaneous patent foramen ovale (PFO) closure with the Amplatzer PFO Occluder significantly reduced migraine days and attacks in patients with episodic migraine who had PFO and were refractory to preventive medical therapy.

Major finding: At 12 months, PFO closure vs. medical therapy group showed a significantly greater mean reduction in monthly migraine days (−3.1 vs. −1.9 days; P = .02) and the number of monthly migraine attacks (−2.0 vs. −1.4; P = .01). Rate of complete migraine cessation was significantly higher in PFO closure vs. medical therapy (9% vs. 0.7%; P less than .001) group. No clinically relevant adverse events were reported.

Study details: Findings are from individual patient-level data from 2 randomized migraine trials PRIMA and PREMIUM involving 337 patients with episodic migraine and PFO randomly allocated to either PFO closure+medical therapy (n=176) or medical therapy alone (n=161).

Disclosures: The study did not receive any funding. Dr. AC Charles, Dr. S Sorensen, Dr. SD Silberstein and Dr. JM Tobis were on the steering committee for the PREMIUM trial. Dr. HP Mattle and Dr. B Meier were on the steering committee for the PRIMA trial.  Dr. B West, Dr. B Meier and Dr. JM Tobis declared receiving funds, serving as proctor/speaker/consultant for various sources. All other authors declared no conflicts of interest.

Source: Mojadidi MK et al. J Am Coll Cardiol. 2021 Feb 16. doi: 10.1016/j.jacc.2020.11.068.

Key clinical point: Propranolol appears more effective in reducing temporomandibular disorder (TMD) pain among migraineurs, with more of the effect mediated by reduced heart rate than by decreased headache impact.

Major finding: Efficacy of propranolol for at least 30% reduction in facial pain index at week 9 was higher among 104 migraineurs (adjusted odds ratio [aOR], 3.3; P = .009; P for treatment group interaction = .139) than 95 non-migraineurs (aOR, 1.3; P = .631; P for treatment group interaction = .139). Only 9% of the treatment effect was mediated by reduced headache, whereas 46% was mediated by reduced heart rate.

Study details: Data come from SOPPRANO, a phase 2b randomized controlled trial that investigated analgesic efficacy of propranolol in 200 patients with chronic myogenous TMD randomly allocated to either propranolol or placebo.

Disclosures: The study was funded by the National Institutes of Health/National Institute of Dental and Craniofacial Research. The authors declared no potential conflicts of interest.

Source: Tchivileva IE et al. Cephalalgia. 2021 Feb 9. doi: 10.1177/0333102421989268.

Key clinical point: Propranolol appears more effective in reducing temporomandibular disorder (TMD) pain among migraineurs, with more of the effect mediated by reduced heart rate than by decreased headache impact.

Major finding: Efficacy of propranolol for at least 30% reduction in facial pain index at week 9 was higher among 104 migraineurs (adjusted odds ratio [aOR], 3.3; P = .009; P for treatment group interaction = .139) than 95 non-migraineurs (aOR, 1.3; P = .631; P for treatment group interaction = .139). Only 9% of the treatment effect was mediated by reduced headache, whereas 46% was mediated by reduced heart rate.

Study details: Data come from SOPPRANO, a phase 2b randomized controlled trial that investigated analgesic efficacy of propranolol in 200 patients with chronic myogenous TMD randomly allocated to either propranolol or placebo.

Disclosures: The study was funded by the National Institutes of Health/National Institute of Dental and Craniofacial Research. The authors declared no potential conflicts of interest.

Source: Tchivileva IE et al. Cephalalgia. 2021 Feb 9. doi: 10.1177/0333102421989268.

Key clinical point: Propranolol appears more effective in reducing temporomandibular disorder (TMD) pain among migraineurs, with more of the effect mediated by reduced heart rate than by decreased headache impact.

Major finding: Efficacy of propranolol for at least 30% reduction in facial pain index at week 9 was higher among 104 migraineurs (adjusted odds ratio [aOR], 3.3; P = .009; P for treatment group interaction = .139) than 95 non-migraineurs (aOR, 1.3; P = .631; P for treatment group interaction = .139). Only 9% of the treatment effect was mediated by reduced headache, whereas 46% was mediated by reduced heart rate.

Study details: Data come from SOPPRANO, a phase 2b randomized controlled trial that investigated analgesic efficacy of propranolol in 200 patients with chronic myogenous TMD randomly allocated to either propranolol or placebo.

Disclosures: The study was funded by the National Institutes of Health/National Institute of Dental and Craniofacial Research. The authors declared no potential conflicts of interest.

Source: Tchivileva IE et al. Cephalalgia. 2021 Feb 9. doi: 10.1177/0333102421989268.

Key clinical point: A 3-month ketogenic diet (KD) resulted in a reduction of painful symptoms of drug refractory chronic migraine.

Major finding: KD significantly reduced the number of migraine days/month from a median of 30 days to 7.5 days (P less than .0001), hours of migraine/day from a median of 24 hours to 5.5 hours (P less than .0016), and pain level at maximum value for 83% of participants that improved for 55% of them (P less than .0024). The median number of drugs taken in a month reduced from 30 to 6 doses.

Study details: This open-label, single-arm clinical trial assessed 38 patients with refractory chronic migraine who adopted a KD for 3 months.

Disclosures: No source of funding was declared. The authors declared no conflicts of interest.

Source: Bongiovanni D et al. Neurol Sci. 2021 Feb 1. doi: 10.1007/s10072-021-05078-5.

Key clinical point: A 3-month ketogenic diet (KD) resulted in a reduction of painful symptoms of drug refractory chronic migraine.

Major finding: KD significantly reduced the number of migraine days/month from a median of 30 days to 7.5 days (P less than .0001), hours of migraine/day from a median of 24 hours to 5.5 hours (P less than .0016), and pain level at maximum value for 83% of participants that improved for 55% of them (P less than .0024). The median number of drugs taken in a month reduced from 30 to 6 doses.

Study details: This open-label, single-arm clinical trial assessed 38 patients with refractory chronic migraine who adopted a KD for 3 months.

Disclosures: No source of funding was declared. The authors declared no conflicts of interest.

Source: Bongiovanni D et al. Neurol Sci. 2021 Feb 1. doi: 10.1007/s10072-021-05078-5.

Key clinical point: A 3-month ketogenic diet (KD) resulted in a reduction of painful symptoms of drug refractory chronic migraine.

Major finding: KD significantly reduced the number of migraine days/month from a median of 30 days to 7.5 days (P less than .0001), hours of migraine/day from a median of 24 hours to 5.5 hours (P less than .0016), and pain level at maximum value for 83% of participants that improved for 55% of them (P less than .0024). The median number of drugs taken in a month reduced from 30 to 6 doses.

Study details: This open-label, single-arm clinical trial assessed 38 patients with refractory chronic migraine who adopted a KD for 3 months.

Disclosures: No source of funding was declared. The authors declared no conflicts of interest.

Source: Bongiovanni D et al. Neurol Sci. 2021 Feb 1. doi: 10.1007/s10072-021-05078-5.

Key clinical point: Galcanezumab reduces the frequency of migraine headache days and may also potentially decrease disabling non-pain symptoms on days when migraine is present in patients with episodic and chronic migraine.

Major finding: Galcanezumab doses of 120 and 240 mg were superior to placebo in reducing the number of monthly migraine days with nausea and/or vomiting in both episodic and chronic migraine studies (all P less than .001). Both doses of galcanezumab were associated with a significant reduction in migraine headache days with photophobia and phonophobia vs. placebo in episodic (P less than .001) and chronic (P less than .001 for galcanezumab 120 mg; P =.001 for galcanezumab 240 mg) migraine studies.

Study details: A post hoc analysis of phase 3 randomized clinical trials EVOLVE-1, EVOLVE-2, and REGAIN that included a total of 2,289 patients with episodic or chronic migraine with or without aura.

Disclosures: This study was funded by Eli Lilly and Company, Indianapolis, IN, USA. K Day, VL Stauffer, V Skljarevski, M Rettiganti, E Pearlman, and SK Aurora reported being current/former full-time employees and/or minor stockholders of Eli Lilly and Company. M Ament reported being a consultant and/or on speaker bureaus for Eli Lilly and Company and others.

Source: Ament M et al. J Headache Pain. 2021 Feb 6. doi: 10.1186/s10194-021-01215-9.

Key clinical point: Galcanezumab reduces the frequency of migraine headache days and may also potentially decrease disabling non-pain symptoms on days when migraine is present in patients with episodic and chronic migraine.

Major finding: Galcanezumab doses of 120 and 240 mg were superior to placebo in reducing the number of monthly migraine days with nausea and/or vomiting in both episodic and chronic migraine studies (all P less than .001). Both doses of galcanezumab were associated with a significant reduction in migraine headache days with photophobia and phonophobia vs. placebo in episodic (P less than .001) and chronic (P less than .001 for galcanezumab 120 mg; P =.001 for galcanezumab 240 mg) migraine studies.

Study details: A post hoc analysis of phase 3 randomized clinical trials EVOLVE-1, EVOLVE-2, and REGAIN that included a total of 2,289 patients with episodic or chronic migraine with or without aura.

Disclosures: This study was funded by Eli Lilly and Company, Indianapolis, IN, USA. K Day, VL Stauffer, V Skljarevski, M Rettiganti, E Pearlman, and SK Aurora reported being current/former full-time employees and/or minor stockholders of Eli Lilly and Company. M Ament reported being a consultant and/or on speaker bureaus for Eli Lilly and Company and others.

Source: Ament M et al. J Headache Pain. 2021 Feb 6. doi: 10.1186/s10194-021-01215-9.

Key clinical point: Galcanezumab reduces the frequency of migraine headache days and may also potentially decrease disabling non-pain symptoms on days when migraine is present in patients with episodic and chronic migraine.

Major finding: Galcanezumab doses of 120 and 240 mg were superior to placebo in reducing the number of monthly migraine days with nausea and/or vomiting in both episodic and chronic migraine studies (all P less than .001). Both doses of galcanezumab were associated with a significant reduction in migraine headache days with photophobia and phonophobia vs. placebo in episodic (P less than .001) and chronic (P less than .001 for galcanezumab 120 mg; P =.001 for galcanezumab 240 mg) migraine studies.

Study details: A post hoc analysis of phase 3 randomized clinical trials EVOLVE-1, EVOLVE-2, and REGAIN that included a total of 2,289 patients with episodic or chronic migraine with or without aura.

Disclosures: This study was funded by Eli Lilly and Company, Indianapolis, IN, USA. K Day, VL Stauffer, V Skljarevski, M Rettiganti, E Pearlman, and SK Aurora reported being current/former full-time employees and/or minor stockholders of Eli Lilly and Company. M Ament reported being a consultant and/or on speaker bureaus for Eli Lilly and Company and others.

Source: Ament M et al. J Headache Pain. 2021 Feb 6. doi: 10.1186/s10194-021-01215-9.

Key clinical point: Lasmiditan is effective in the treatment of an acute migraine attack and demonstrates consistency of response across multiple migraine attacks

Major finding: Lasmiditan doses of 100 and 200 mg were superior to placebo for pain freedom at 2 hours during the first attack (odds ratio [OR], 3.8 and 4.6, respectively; P less than .001) and in at least 2 of 3 attacks (OR, 3.8 and 7.2, respectively; P less than .001). The incidence of severe adverse events was similar across treatment groups.

Study details: Findings are from CENTURION, a phase 3 study that randomly assigned patients with migraine with/without aura to either of 3 treatment groups for 4 attacks: lasmiditan 200 mg (n=536), lasmiditan 100 mg (n=539), or control (n=538).

Disclosures: The CENTURION study was sponsored by Eli Lilly and Company. Some authors including the lead author were full-time employees and minor stockholders at Eli Lilly and Company. Some authors reported receiving speaker fees and honorariums from different sources.

Source: Ashina M et al. Cephalalgia. 2021 Feb 4. doi: 10.1177/0333102421989232.

Key clinical point: Lasmiditan is effective in the treatment of an acute migraine attack and demonstrates consistency of response across multiple migraine attacks

Major finding: Lasmiditan doses of 100 and 200 mg were superior to placebo for pain freedom at 2 hours during the first attack (odds ratio [OR], 3.8 and 4.6, respectively; P less than .001) and in at least 2 of 3 attacks (OR, 3.8 and 7.2, respectively; P less than .001). The incidence of severe adverse events was similar across treatment groups.

Study details: Findings are from CENTURION, a phase 3 study that randomly assigned patients with migraine with/without aura to either of 3 treatment groups for 4 attacks: lasmiditan 200 mg (n=536), lasmiditan 100 mg (n=539), or control (n=538).

Disclosures: The CENTURION study was sponsored by Eli Lilly and Company. Some authors including the lead author were full-time employees and minor stockholders at Eli Lilly and Company. Some authors reported receiving speaker fees and honorariums from different sources.

Source: Ashina M et al. Cephalalgia. 2021 Feb 4. doi: 10.1177/0333102421989232.

Key clinical point: Lasmiditan is effective in the treatment of an acute migraine attack and demonstrates consistency of response across multiple migraine attacks

Major finding: Lasmiditan doses of 100 and 200 mg were superior to placebo for pain freedom at 2 hours during the first attack (odds ratio [OR], 3.8 and 4.6, respectively; P less than .001) and in at least 2 of 3 attacks (OR, 3.8 and 7.2, respectively; P less than .001). The incidence of severe adverse events was similar across treatment groups.

Study details: Findings are from CENTURION, a phase 3 study that randomly assigned patients with migraine with/without aura to either of 3 treatment groups for 4 attacks: lasmiditan 200 mg (n=536), lasmiditan 100 mg (n=539), or control (n=538).

Disclosures: The CENTURION study was sponsored by Eli Lilly and Company. Some authors including the lead author were full-time employees and minor stockholders at Eli Lilly and Company. Some authors reported receiving speaker fees and honorariums from different sources.

Source: Ashina M et al. Cephalalgia. 2021 Feb 4. doi: 10.1177/0333102421989232.

Key clinical point: Treatment with erenumab significantly improved functional outcomes in 3 months in patients with episodic migraine refractory to previous prophylactic therapies.

Major finding: At 12 weeks, erenumab significantly improved “Migraine Physical Function Impact Diary”-“Physical Impairment” and “Everyday Activities” scores compared with placebo (treatment difference [TD], −3.5; P = .003 and TD, −3.9; P less than .001, respectively). A significantly higher proportion of patients had a 5 or more point reduction in the Headache Impact Test score from baseline compared with placebo (odds ratio, 2.4; P = .002).

Study details: Data come from the 12-week, double-blind, multicenter, Liberty study involving 246 episodic migraine patients who did not previously benefit from 2-4 prophylactic treatments. They were randomly assigned to receive either erenumab 140 mg (n = 121) or placebo (n = 125) once every 4 weeks for 12 weeks.

Disclosures: The study was supported by Novartis Pharma AG, Basel, Switzerland. S Wen, P Hours-Zesiger, and J Klatt were employees of, and hold stocks in, Novartis. M Lanteri-Minet, PJ Goadsby, U Reuter, and MD Ferrari reported relationships with various pharmaceutical companies and/or research organizations.

Source:Lanteri-Minet M et al. J Neurol Neurosurg Psychiatry. 2021 Jan 5. doi: 10.1136/jnnp-2020-324396.

Key clinical point: Treatment with erenumab significantly improved functional outcomes in 3 months in patients with episodic migraine refractory to previous prophylactic therapies.

Major finding: At 12 weeks, erenumab significantly improved “Migraine Physical Function Impact Diary”-“Physical Impairment” and “Everyday Activities” scores compared with placebo (treatment difference [TD], −3.5; P = .003 and TD, −3.9; P less than .001, respectively). A significantly higher proportion of patients had a 5 or more point reduction in the Headache Impact Test score from baseline compared with placebo (odds ratio, 2.4; P = .002).

Study details: Data come from the 12-week, double-blind, multicenter, Liberty study involving 246 episodic migraine patients who did not previously benefit from 2-4 prophylactic treatments. They were randomly assigned to receive either erenumab 140 mg (n = 121) or placebo (n = 125) once every 4 weeks for 12 weeks.

Disclosures: The study was supported by Novartis Pharma AG, Basel, Switzerland. S Wen, P Hours-Zesiger, and J Klatt were employees of, and hold stocks in, Novartis. M Lanteri-Minet, PJ Goadsby, U Reuter, and MD Ferrari reported relationships with various pharmaceutical companies and/or research organizations.

Source:Lanteri-Minet M et al. J Neurol Neurosurg Psychiatry. 2021 Jan 5. doi: 10.1136/jnnp-2020-324396.

Key clinical point: Treatment with erenumab significantly improved functional outcomes in 3 months in patients with episodic migraine refractory to previous prophylactic therapies.

Major finding: At 12 weeks, erenumab significantly improved “Migraine Physical Function Impact Diary”-“Physical Impairment” and “Everyday Activities” scores compared with placebo (treatment difference [TD], −3.5; P = .003 and TD, −3.9; P less than .001, respectively). A significantly higher proportion of patients had a 5 or more point reduction in the Headache Impact Test score from baseline compared with placebo (odds ratio, 2.4; P = .002).

Study details: Data come from the 12-week, double-blind, multicenter, Liberty study involving 246 episodic migraine patients who did not previously benefit from 2-4 prophylactic treatments. They were randomly assigned to receive either erenumab 140 mg (n = 121) or placebo (n = 125) once every 4 weeks for 12 weeks.

Disclosures: The study was supported by Novartis Pharma AG, Basel, Switzerland. S Wen, P Hours-Zesiger, and J Klatt were employees of, and hold stocks in, Novartis. M Lanteri-Minet, PJ Goadsby, U Reuter, and MD Ferrari reported relationships with various pharmaceutical companies and/or research organizations.

Source:Lanteri-Minet M et al. J Neurol Neurosurg Psychiatry. 2021 Jan 5. doi: 10.1136/jnnp-2020-324396.

Key clinical point: Erenumab treatment significantly improved the number of headache days in patients with onabotulinumtoxinA-resistant chronic migraine.

Major finding: Erenumab significantly reduced the number of headache days that limited activities of daily living at 3 months (−6.4 days), 6 months (−6.8 days), and 9 months (−6.5 days; P for all = .001).

Study details: Real-world outcomes were assessed in 98 patients with difficult-to-control chronic migraine and a prior unsatisfactory response to onabotulinumtoxinA.

Disclosures: This study did not receive any funding. Erenumab was provided free of charge by Novartis. S Weatherby attended conferences/received speakers fees from Novartis.

Source:Talbot J et al. J Headache Pain. 2021 Jan 9. doi: 10.1186/s10194-020-01214-2.

Key clinical point: Erenumab treatment significantly improved the number of headache days in patients with onabotulinumtoxinA-resistant chronic migraine.

Major finding: Erenumab significantly reduced the number of headache days that limited activities of daily living at 3 months (−6.4 days), 6 months (−6.8 days), and 9 months (−6.5 days; P for all = .001).

Study details: Real-world outcomes were assessed in 98 patients with difficult-to-control chronic migraine and a prior unsatisfactory response to onabotulinumtoxinA.

Disclosures: This study did not receive any funding. Erenumab was provided free of charge by Novartis. S Weatherby attended conferences/received speakers fees from Novartis.

Source:Talbot J et al. J Headache Pain. 2021 Jan 9. doi: 10.1186/s10194-020-01214-2.

Key clinical point: Erenumab treatment significantly improved the number of headache days in patients with onabotulinumtoxinA-resistant chronic migraine.

Major finding: Erenumab significantly reduced the number of headache days that limited activities of daily living at 3 months (−6.4 days), 6 months (−6.8 days), and 9 months (−6.5 days; P for all = .001).

Study details: Real-world outcomes were assessed in 98 patients with difficult-to-control chronic migraine and a prior unsatisfactory response to onabotulinumtoxinA.

Disclosures: This study did not receive any funding. Erenumab was provided free of charge by Novartis. S Weatherby attended conferences/received speakers fees from Novartis.

Source:Talbot J et al. J Headache Pain. 2021 Jan 9. doi: 10.1186/s10194-020-01214-2.

Key clinical point: People with a history of migraine are more than twice as likely as those with no such history to have irritable bowel syndrome (IBS).

Major finding: IBS odds were significantly higher in patients with migraine vs. those without: overall (pooled odds ratio [OR], 2.49; 95% confidence interval [CI], 2.22-2.78); migraine with aura (pooled OR, 3.03; 95% CI, 1.72-5.35); and migraine without aura (pooled OR, 2.20; 95% CI, 1.49-3.25).

Study details: Meta-analysis of 11 studies including 28,336 migraineurs and 1,535,758 nonmigraineurs.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.

Source:Wongtrakul W et al. Eur J Gastroenterol Hepatol. 2021 Jan 18. doi: 10.1097/MEG.0000000000002065.

Key clinical point: People with a history of migraine are more than twice as likely as those with no such history to have irritable bowel syndrome (IBS).

Major finding: IBS odds were significantly higher in patients with migraine vs. those without: overall (pooled odds ratio [OR], 2.49; 95% confidence interval [CI], 2.22-2.78); migraine with aura (pooled OR, 3.03; 95% CI, 1.72-5.35); and migraine without aura (pooled OR, 2.20; 95% CI, 1.49-3.25).

Study details: Meta-analysis of 11 studies including 28,336 migraineurs and 1,535,758 nonmigraineurs.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.

Source:Wongtrakul W et al. Eur J Gastroenterol Hepatol. 2021 Jan 18. doi: 10.1097/MEG.0000000000002065.

Key clinical point: People with a history of migraine are more than twice as likely as those with no such history to have irritable bowel syndrome (IBS).

Major finding: IBS odds were significantly higher in patients with migraine vs. those without: overall (pooled odds ratio [OR], 2.49; 95% confidence interval [CI], 2.22-2.78); migraine with aura (pooled OR, 3.03; 95% CI, 1.72-5.35); and migraine without aura (pooled OR, 2.20; 95% CI, 1.49-3.25).

Study details: Meta-analysis of 11 studies including 28,336 migraineurs and 1,535,758 nonmigraineurs.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.

Source:Wongtrakul W et al. Eur J Gastroenterol Hepatol. 2021 Jan 18. doi: 10.1097/MEG.0000000000002065.